Wall Street Zen Upgrades Inhibrx Biosciences (NASDAQ:INBX) to Sell

Inhibrx Biosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen raised Inhibrx Biosciences’ rating from “strong sell” to “sell.” Analyst views remain mixed: MarketBeat reports a “Moderate Buy” consensus and an average price target of $185.
  • Shares opened at $68.97, well below their 12-month high of $155.29. The company’s latest quarterly loss per share of $2.46 narrowly missed consensus, while revenue of $2 million exceeded estimates.
  • Company insiders bought 62,540 shares worth about $6.35 million over the past 90 days; insiders own 18.26% of the stock. Institutional investors hold 82.46%.
  • MarketBeat previews top five stocks to own in December.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "strong sell" rating to a "sell" rating in a note issued to investors on Saturday, Wall Street Zen reports.

A number of other research firms also recently weighed in on INBX. HC Wainwright dropped their target price on Inhibrx Biosciences from $245.00 to $220.00 and set a "buy" rating for the company in a report on Monday, November 16th. Citigroup restated a "market perform" rating on shares of Inhibrx Biosciences in a research note on Friday, September 18th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Inhibrx Biosciences in a research report on Friday, September 11th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Inhibrx Biosciences has a consensus rating of "Moderate Buy" and an average target price of $185.00.

View Our Latest Research Report on INBX

Inhibrx Biosciences Stock Performance

Shares of NASDAQ:INBX opened at $68.97 on Friday. Inhibrx Biosciences has a 12-month low of $57.30 and a 12-month high of $155.29. The business has a 50 day moving average of $91.17 and a 200-day moving average of $92.01.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last released its quarterly earnings results on Friday, November 13th. The company reported ($2.46) earnings per share for the quarter, missing the consensus estimate of ($2.45) by ($0.01). The company had revenue of $2.00 million during the quarter, compared to analyst estimates of $1.90 million. As a group, analysts expect that Inhibrx Biosciences will post -9.70 EPS for the current year.

Insider Buying and Selling

In related news, Director Jon Kayyem bought 5,000 shares of the business's stock in a transaction dated Wednesday, September 23rd. The stock was purchased at an average cost of $100.00 per share, for a total transaction of $500,000.00. Following the transaction, the director owned 434,360 shares in the company, valued at $43,436,000. The trade was a 1.16% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Mark Lappe bought 10,040 shares of the business's stock in a transaction dated Wednesday, October 14th. The shares were bought at an average price of $84.56 per share, with a total value of $848,982.40. Following the completion of the transaction, the chief executive officer owned 745,588 shares in the company, valued at approximately $63,046,921.28. This trade represents a 1.36% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have purchased 62,540 shares of company stock valued at $6,347,507 and have sold 1,500 shares valued at $168,590. 18.26% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE bought a new stake in shares of Inhibrx Biosciences during the 2nd quarter worth $79,698,000. BlackRock Inc. acquired a new stake in Inhibrx Biosciences in the second quarter valued at about $78,261,000. Parkman Healthcare Partners LLC acquired a new stake in Inhibrx Biosciences in the second quarter valued at about $24,346,000. Soleus Capital Management L.P. bought a new position in Inhibrx Biosciences in the third quarter valued at about $21,017,000. Finally, Jefferies Financial Group Inc. bought a new position in Inhibrx Biosciences in the second quarter valued at about $6,956,000. Institutional investors and hedge funds own 82.46% of the company's stock.

Inhibrx Biosciences Company Profile

(Get Free Report)

Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company's oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.

Further Reading

Analyst Recommendations for Inhibrx Biosciences (NASDAQ:INBX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Inhibrx Biosciences Right Now?

Before you consider Inhibrx Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx Biosciences wasn't on the list.

While Inhibrx Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines